Mobile Trading

DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE6670.30-52.45 (-0.78 %)
PREV CLOSE ( ) 6722.75
OPEN PRICE ( ) 6621.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 5013
TODAY'S LOW / HIGH ( )6608.25 6718.75
52 WK LOW / HIGH ( )4396.6 6859.8
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 12-10 1990
Management Info
Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director
Registered Office

Address 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone 040 66966300 / 400

Email mail@divislabs.com

Website www.divislabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS
26May Divi's Laboratories inks pact with glo
Divi's Laboratories has signed long term manufacturing and supply agreem..
26May Divi's Laboratories zooms on inking pa
Divi's Laboratories is currently trading at Rs 6744.00, up by 263.30 poi..
24May Divi's Laboratories informs about upd
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obliga..
17May Divis Laboratories board approves divi
Further to letter dated May 08, 2025, Divis Laboratories has informed th..
16May Divis Laboratories informs about annua
Divis Laboratories has informed that it enclosed the Annual Secretarial..
Financials
in Millions
QTR Mar 25 ANNUAL 25
Net Profit667022090
Gross Profit 8610 29290
Operating Profit 968033310
Net Sales 2536091980
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Astrazeneca Pharma I (BSE)
up  10524.65 (3.40%)
M.Cap ( in Cr)26311.63
RPG Life Sciences (BSE)
up  2339.50 (4.07%)
M.Cap ( in Cr)3869.30
Abbott India (BSE)
up  31545.15 (0.22%)
M.Cap ( in Cr)67031.24
Concord Biotech (BSE)
up  2110.55 (2.44%)
M.Cap ( in Cr)22079.77
Onesource Specialty (BSE)
up  2024.35 (2.45%)
M.Cap ( in Cr)23171.93
Shareholding Pattern
NON-INSTITUTION 9.39%
FI/BANKS/INSURANCE 7.3%
PROMOTERS 51.89%
MUTUAL FUNDS/UTI 12.83%
GOVERNMENT 0%
FII 0%

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by  Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.